These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
449 related items for PubMed ID: 15661558
1. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG, Shah JP, Fong Y. Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558 [Abstract] [Full Text] [Related]
2. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL. Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637 [Abstract] [Full Text] [Related]
3. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y. Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120 [Abstract] [Full Text] [Related]
4. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Morris JC, Wildner O. Mol Ther; 2000 Jan; 1(1):56-62. PubMed ID: 10933912 [Abstract] [Full Text] [Related]
5. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Todo T, Rabkin SD, Martuza RL. Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026 [Abstract] [Full Text] [Related]
6. [Combined interleukin-2 and herpes simplex virus thymidine kinase gene therapy for head and neck squamous cell carcinoma]. Liu S, Liang C, Yang H, Xian J. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):426-9. PubMed ID: 12761956 [Abstract] [Full Text] [Related]
7. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). Bennett JJ, Adusumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, Zager JS, Chou TC, Fong Y. FASEB J; 2004 Jun; 18(9):1001-3. PubMed ID: 15059970 [Abstract] [Full Text] [Related]
8. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Nakano K, Todo T, Chijiiwa K, Tanaka M. Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903 [Abstract] [Full Text] [Related]
9. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA, O'Malley BW. Cancer Res; 2002 Jul 15; 62(14):4023-8. PubMed ID: 12124336 [Abstract] [Full Text] [Related]
10. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB, Glorioso JC, Tanaka M. J Gene Med; 2005 May 15; 7(5):638-48. PubMed ID: 15754306 [Abstract] [Full Text] [Related]
11. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T. J Gene Med; 2006 Nov 15; 8(11):1329-40. PubMed ID: 16955534 [Abstract] [Full Text] [Related]
13. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW, Li D, McQuone SJ, Ralston R. Laryngoscope; 2005 Mar 15; 115(3):391-404. PubMed ID: 15744147 [Abstract] [Full Text] [Related]
15. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Neoplasia; 1999 Jun 15; 1(2):162-9. PubMed ID: 10933051 [Abstract] [Full Text] [Related]
16. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Bray D, Yu SZ, Koprowski H, Rhee J, Kumar S, Pericle F, Suntharalingam M, Van Echo DA, Li D, O'Malley BW. Arch Otolaryngol Head Neck Surg; 2003 Jun 15; 129(6):618-22. PubMed ID: 12810463 [Abstract] [Full Text] [Related]
17. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Li D, Jiang W, Bishop JS, Ralston R, O'Malley BW. Clin Cancer Res; 1999 Jun 15; 5(6):1551-6. PubMed ID: 10389944 [Abstract] [Full Text] [Related]
19. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura K, Ichimura K, Ozawa K. Gene Ther; 2003 Jan 15; 10(1):51-8. PubMed ID: 12525837 [Abstract] [Full Text] [Related]
20. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Kanai R, Tomita H, Shinoda A, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T. Gene Ther; 2006 Jan 15; 13(2):106-16. PubMed ID: 16163378 [Abstract] [Full Text] [Related] Page: [Next] [New Search]